Having promised much, Esmo underdelivers with a late-breaker that appears to hand some advantage back to Mirati.
Grail finds the path for its liquid biopsy less clear than it might have hoped.
But it is still unclear how much of a threat Onpattro will be to Pfizer’s Vyndaqel.
Later cuts of Tropics-02 make for better reading, but in Her2-driven breast cancer Gilead’s Trodelvy will remain a footnote to Enhertu.
Late-breakers give tislelizumab, camrelizumab and Keytruda outside chances to add to the first-line armamentarium.
Adagrasib data hold up, but filing timelines are still unclear.
Amgen’s confirmatory Codebreak-200 trial will feature as a surprising late-breaker at Esmo’s presidential session.